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Introduction: The development of tinnitus and/or hearing loss (THL) in patients receiving chronic 
salicylate therapy has been demonstrated. However, to date, little scientific data validates this 
relationship in the large single overdose setting. 
Objective: To correlate salicylate levels in patients with the subjective complaint of THL, following an 
acute salicylate overdose.
Methods: A retrospective chart review of cases of acute salicylate toxicity and THL reported to the 
Illinois Poison Control Center (IPC) from 2001-2002 was performed. Data abstracted included age, 
gender, ingestion time, salicylate levels, and arterial blood gases. 
Results: Ninety-nine cases of THL were reviewed and analyzed with mean age of 23.7 years (SD: 
10.9), 30.3% male, and 82.2% intentional overdoses. The average dose ingested was 20.0 grams 
(SD:20.2) and the mean time from ingestion to medical care was 12.4 hours (SD: 11.1). The mean 
initial ASA level was 48.3 mg/dl (SD: 16.4) with 86.9% having initial level ≥ 30mg/dl and 40.4% ≥ 50 
mg/dl. 85.9% of cases presented to the hospital with their ASA level at or past peak. The mean pH 
was 7.45, pO2 = 108, pCO2 = 28.0, and HCO3 = 19.9.  
Conclusion: In this limited study, 85.9% of patients presenting with tinnitus and/or hearing loss 
following a single salicylate ingestion had initial salicylate levels at or past their peak and 86.9% were 
in the toxic range. 
[WestJEM. 2008;9:146-149.]
INTRODUCTION
Salicylates, aspirin in particular, have been used for 
their analgesic and anti-inflammatory properties for many 
years.1 Unfortunately, toxicity from salicylates remains a 
common occurrence in the emergency department (ED).2-
4 Moreover, it is well known that the development of 
tinnitus is associated with salicylate use, and its onset 
has been heralded as an early marker of toxicity.5-7 This 
subjective complaint is classically described as a constant 
ringing, or roaring sound, perceived by the patient. Other 
presentations may include a subjective hearing loss or 
muffled hearing.8
Numerous reports have demonstrated the development 
of tinnitus and/or hearing loss (THL) in patients receiving 
chronic salicylate therapy.9-14 Anecdotally, its development 
has also been documented in the overdose setting.15 
However, to date, little scientific data validates this 
relationship between THL and salicylate levels in patients 
with a large single salicylate overdose, as seen the ED. The 
hypothesis of this study was that the subjective complaint of Volume IX, n o . 3  :  August 2008                                        147                               Western Journal of Emergency Medicine
tinnitus and/or hearing loss, in the setting of a large single 
salicylate overdose, correlates with an elevated salicylate 
level.
METHODS
A retrospective review of all cases of possible salicylate 
overdose reported to the Illinois Poison Center (IPC) from 
January 1, 2001 to December 31, 2002 was performed. 
Before the study’s inception, approval was obtained from the 
institutional review board of Resurrection Medical Center. 
Potential cases were identified by a search of the computerized 
database (dotlab) of the poison center. The search criteria 
included “aspirin” or “salicylate” entered in the search field 
based on the American Association of Poison Control Centers 
(AAPCC) coding of salicylate products. The database search 
had no restrictions for age, sex, or exclusions based on co-
ingestants. The information recorded in the database was 
provided by the healthcare workers involved in the care of the 
patient through telephone consultation with the poison center. 
This information was then entered into the database by the 
employee of the poison center. 
The study setting included all emergency departments, 
intensive care units, and urgent care centers in the state of 
Illinois who contacted the poison center regarding salicylate 
toxicity management. Treatment and management decisions 
were made by the healthcare provider and poison center 
specialist involved in each individual case.
The raw data abstracted from call records were reviewed 
individually for age, gender, timing from ingestion to 
presentation for treatment, salicylate levels, bicarbonate levels, 
pH level, pCO2 level, pO2 level, and presence or absence 
of THL. All names were de-identified and deleted from the 
database before data abstraction. These data elements were 
entered onto an Excel spreadsheet for analysis. An additional 
author to ensure entry accuracy reviewed approximately 10% 
of the collected data. 
Since this was a retrospective chart review, the amount of 
detail provided in each chart varied and was not consistent for 
all charts. The time of ingestion to presentation for medical 
treatment was determined based on history taken by the 
healthcare provider and rounded off to the nearest half-hour. 
The presence of THL was also determined by the healthcare 
provider who queried this information during the initial 
contact with the patient. This measurement was performed 
utilizing a simple yes or no format. THL was defined by the 
poison center staff and medical provider as the subjective 
complaint of either ringing/roaring in the ears, “muffled” 
hearing, or the perception of a hearing loss by the patient
All poison center charts containing the search criteria 
words were reviewed for inclusion into the study. Reasons 
for exclusion from the study were as follows: patients that 
did not present to a health care facility after making poison 
center contact, patients who did not ingest a salicylate as 
demonstrated by two consecutive serum levels below 1 mg/
dl, or did not have documented salicylate levels, patients who 
failed to have the presence or absence of tinnitus queried by 
the health care worker, patients who were unable to confirm 
the presence or absence of THL either due to age, language 
barrier, or alteration in consciousness.
Data Analysis 
Following data collection, descriptive statistics were 
performed using Statistical Package for Social Sciences for 
Windows Version 11.5 (Chicago, IL, 2004).
RESULTS
The database search yielded follow-up records on 
592 cases of salicylate toxicity. In 335 cases the presence 
or absence of THL was not queried during the encounter 
or its documentation was not provided. In 44 cases, the 
patient was unable to confirm the presence of THL due to 
either age, language barrier, or an alteration in their level 
of consciousness. Only 99 of the remaining 213 cases had 
documented THL and were included in the study. Table 1 
gives the demographic profile of all 213 documented cases, 
while Figure 1 is a box-plot of the initial acetylsalicylic acid 
(ASA) level between patients with documented THL and 
patients with documented no THL.  
There were minimal differences between THL and no 
THL patients in terms of demographics or cause of ASA 
toxicity. Patients with documented tinnitus or hearing loss had 
higher initial and peak ASA levels. For patients with THL, the 
mean initial ASA level was 48.3 mg/dl (SD: 16.4) compared 
to 30.2 mg/dl (SD:18.4) for patients without THL. Also, 
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Figure 1. Boxplot of patients with and without tinnitus and/or 
hearing loss (THL) vs. initial aspirin levels.
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86.9% of THL patients had initial level ≥ 30mg/dl and 40.4% 
had levels ≥ 50 mg/dl. On repeat testing, only 14.1% of cases 
had a further increase in ASA levels (mean increase = 8.5; SD: 
4.6).  Thus, 85.9% of cases presented to the hospital with their 
ASA level at or past peak. The average patient presented with 
compensated metabolic acidosis with mean pH = 7.45, mean 
pO2 = 108, mean pCO2 = 28.0, and mean HCO3 = 19.9.  
DISCUSSION
The development of tinnitus and/or hearing loss (THL) 
has been heralded as an early marker of salicylate toxicity.5-7 
However, this principle has only been demonstrated in patients 
receiving escalating doses of salicylates as a therapeutic 
measure.12,13 In the overdose setting, THL has been cited as a 
symptom, but no current studies document its true relationship 
to the ingestion. In our limited study, we provide support for 
this concept in the large overdose setting. The data presented 
from our sample demonstrates that those patients who develop 
THL have a 86% chance of having a salicylate level in the 
toxic range, or ≥ 30mg/dl.
The importance of this finding lies in the morbidity and 
mortality associated with salicylate toxicity. Intoxication 
can result in many deleterious effects on the human body, 
including death.16,17 As a result, the early recognition and 
treatment of salicylate toxicity remains paramount. In 
particular, prior studies have demonstrated that patients with 
critical serum salicylate levels have better outcomes when 
treatment is initiated earlier in their hospitalization.18,19
In our study we utilized THL as a subjective marker of 
toxicity. Our results demonstrate that the patient complaint of 
THL, following a single salicylate ingestion, is suggestive of 
a toxic salicylate level. The mean initial salicylate level in the 
THL patients was 48.3 mg/dl. It was also noted that 85% of 
the patients presented to the hospital with their salicylate level 
at their peak. This finding coincides with a prior study that 
documented that the two most common findings in patients 
with significant salicylate overdoses were the historical 
account of ingestion and the subjective complaint of tinnitus.20
The treatment of salicylate toxicity includes bowel 
decontamination, fluid resuscitation, urinary alkalinization, 
and extracorporeal elimination.8,21,22 Bowel decontamination 
in the form of activated charcoal is recommended for 
the majority of cases in salicylate overdose.2,21 However, 
beyond bowel decontamination, the consensus on other 
treatment modalities remains varied.2,3,23 In particular, recent 
publications have recommended the initiation of urinary 
alkalinization when the serum salicylate level is found above 
35 mg/dl.8,21
As stated earlier, the measured serum salicylate level may 
take a significant time to obtain.24 Consequently, flowcharts 
have been developed utilizing the patient’s symptoms or 
other rapidly available clinical data to help guide treatment 
decisions.7,22 Most of these diagrams list THL as a marker of 
early toxicity typically presenting at a level of 25 mg/dl.5,8 The 
data from our study shows that 86.9% of patients had a level ≥ 
30mg/dl. 
The principle that THL typically occurs around 25 mg/
dl is based on previous studies over the past five decades.9-14 
Mongan, et al13 demonstrated that THL was observed at an 
average salicylate concentration of 29.5 mg/dl in patients 
receiving chronic salicylate therapy. A study by Myers10 
reported sensorineural hearing loss as the plasma salicylate 
level approached 30 mg/dl. As stated previously, both these 
studies utilized escalating doses of salicylates as a therapeutic, 
and both are distinctly different than the typical ED overdose 
setting. In our study, the mean salicylate level for those with 
THL was 48.3 mg/dl, much higher than this previously stated 
level of 25 mg/dl. 
LIMITATIONS
Our study possesses several limitations. First, the self 
reporting of THL by the patient creates some potential 
problems. No accurate method was available to determine 
the validity of the patient’s account. It is possible that some 
patients may have falsely denied or affirmed the presence of 
THL. Next, since this was a retrospective chart review, the 
amount of detail provided in each chart varied. Moreover, no 
ED or inpatient charts were obtained in this study to confirm 
poison center records. Lab values and patient histories were 
strictly based on the treating healthcare provider’s phone 
testimony. In addition, the type of salicylate, and its form 
(i.e. enteric coated), were both sparsely documented making 
any analysis of these factors difficult. There was a limited 
population in our sample that had taken co-ingestants as well 
as prescribed medicine in conjunction with their salicylate 
ingestions. In reviewing the data, it seems however, that there 
were no known co-ingestants that would have contributed to 
tinnitus, but we acknowledge that this is a limitation in this 
study. The provided treatment modalities were also not always 
Table 1. Profile of patients with documented Tinnitus and/or 
hearing loss (THL) and no documented THL.
Profile THL No THL
Frequency 99 114
Gender (% male) 30.3% 27.2%
Age (Range) 23.7 (13-59) 24.9 (12-84)
Intentional overdoses 82.8% 91.2%
Initial acetylsalicylic acid (SD) 48.3 (16.4) 30.2 (18.4)
Hours from Ingestion (SD) 12.4 (11.1) 7.2 (8.8)
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identical. Their technique and timing unfortunately could have 
affected a patient’s symptoms and lab values. The data also 
shows that the patients with tinnitus presented later in their 
course (12.4 versus 7.2 hours). But on the same note, 85.9% of 
the cases had the initial level above or at their peak salicylate 
level and the difference between initial and peak levels were 
very small in each group. Therefore we do not believe that 
the time presentation difference to be a large confounding 
variable. Finally, our study is limited in the fact that from a 
large initial study sample, only 213 had documentation of 
tinnitus or hearing loss. The lack of documentation of 335 
patients prevents statistical testing between the groups. It may 
be that there were a number of patients without THL but with 
elevated salicylate levels. Thus, it is impossible to determine 
at what cutoff salicylate level we would expect THL but the 
evidence in this study does show that if THL occurs, we can 
expect an elevated salicylate level. 
CONCLUSION
In the emergency department setting, it is essential 
to consider the diagnosis of salicylate ingestion when an 
overdose is suspected and a patient complains of THL. This 
limited study demonstrates that 85.6% of patients with single 
large salicylate ingestion combined with the complaint of 
tinnitus, and/or hearing loss, had initial salicylate level at or 
past their peak and 86.9% were in the toxic range. 
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